Ticker Notes
A collection of stock notes from around the web.
March 12, 2019
Gene Editing Stocks
The Fool looks briefly at
three gene editing stocks
, the most interesting of which is Editas. The company's lead drug looks to cure genetic blindness, but it is only in Phase 1 trials. However, the drug looks to be given the fast track by the FDA.
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment